University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile

University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 27, 2016
70 pages — Published Sep 27, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

University College London (UCL) is an educational institute that provides undergraduate, post-graduate, and life learning programs. It offers programs in the areas of arts and humanities, Bartlett faculty of the built environment, brain sciences, engineering, laws, life sciences, mathematical and physical sciences, medical sciences, population health sciences and social, and historical sciences. The university's services include alumini services, infrastructure management, finance and business affairs, human resource development, information services, library services, public and cultural engagement, and student and registry services.

University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed inform

  
Source:
Document ID
GDPH142300D
Country
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables42
  List of Figures61
University College London, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201662
University College London, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201681
University College London, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201691
University College London, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 2016102
University College London, Medical Devices Deals, 2010 to YTD 2016121
University College London, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016134
University College London, Pharmaceuticals &Healthcare, Deal Details1749
  Venture Financing171
    Orchard Therapeutics Raises USD31 Million in Series A Venture Financing171
    Puridify Raises USD3.4 Million in Series A Financing181
    Puridify Raises USD1.43 Million in Seed Funding191
    Canbex Therapeutics Raises US$3 Million In Venture Financing202
    Domainex Raises Funds In First Tranche Of US$2.3 Million Venture Financing Round222
    UCL Business Raises US$71 Million In First Round Financing241
  Partnerships251
    Cell Medica Enters into Partnership with University College London251
    Santen Pharma to Enter into Agreement with University College London261
    Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies272
    Teva Pharma Partners with University College London and Imanova291
    University College London Enters into Research Agreement with Takeda Pharma301
    Magnus Life Science Partners with University College London311
    UCL Business Forms Joint Venture with Syncona321
    Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations332
    Takeda Enters into R&D Agreement with University College London351
    iQur Enters into Co-Development Agreement with Six Consortium362
    Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools381
    Cellectis Enters Into Co-Development Agreement With University College London391
    Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs401
    Sarepta Therapeutics Enters Into Co-Development Agreement With University College London411
    Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing421
    TAP Biosystems Enters Into Co-Development Agreement With University College London432
    Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates452
    Medical Research Council, Imperial College, King's College and UCL Form Joint Venture471
    UCL Ear Institute And UCL Business Enter Into Co-Developemnt Agreement With Autifony Therapeutics481
    UCL Business And National Centre for Young People Enters Into Commercialization Agreement With Special Products For Epistatus491
    Eisai Enters Into Research Agreement With University College London501
    Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture512
    PolyTherics Enters Into Collaboration With University College London531
    AstraZeneca Enters Agreement With UCL Business To Develop Regenerative Medicines For Diabetic Retinopathy542
    AstraZeneca Enters Into Co-Development Agreement With University College London561
  Licensing Agreements571
    Autolus Enters into Licensing Agreement with UCL Business571
    Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies581
    Oxford Pharmascience Extends Licensing Agreement With UCL Business591
    BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program602
    Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology621
    University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology631
    UCL Business Enters Into Licensing Agreement With Periowave Dental Technologies641
    AbD Serotec Enters Into An Agreement With UCL Business651
University College London - Key Competitors661
Key Employees671
Locations And Subsidiaries682
  Head Office681
  Other Locations &Subsidiaries682
Appendix701
  Methodology701
  About GlobalData701
  Contact Us701
  Disclaimer701

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 27, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/University-College-London-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-17183>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 27, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/University-College-London-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-17183>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research